We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A once-in-a-decade chance to get rich by investing in FTSE 100 shares?

After lagging overseas stocks for over 10 years, our writer investigates whether FTSE 100 shares could be the smart place for his money today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 index has attracted its fair share of criticism in recent years. Arguably, much of the flak has been warranted.

Recent research from Goldman Sachs has revealed that the Footsie delivered a 6% total annual return over the past decade. Compared to 8% for Europe’s Stoxx 50 and 13% for America’s S&P 500, Britain’s largest shares have been international laggards.

XXX

However, there are indications the tide could be turning for FTSE 100 stocks. Consequently, UK investors might consider looking closer to home for strong future returns. Here’s why.

A rare bargain opportunity

Using the 12-month forward price-to-earnings (P/E) ratio as a gauge, FTSE 100 shares look remarkably cheap relative to pricier stocks stateside.

UK shares trade at a 55% discount to their US counterparts. This gap is the widest it’s been since 1988 by a considerable margin. Value investors have good reasons to view today as a potential buying opportunity we haven’t seen for many, many years.

However, as a note of caution, this gulf has widened substantially since the 2016 Brexit vote and shows little sign of narrowing. At least for now.

Worryingly, UK-focused equity funds have suffered retail investor outflows for three years on the trot. There’s a risk Britain’s stock market malaise could continue for a while yet. Restoring investor confidence is far from guaranteed.

The stagnation of Japanese stocks for 30 years, starting in the early 1990s, is evidence of how long the suffering can persist in developed equity markets.

Where next for UK shares?

That said, the comparison with Japan only goes so far. Its ‘Lost Decades’ followed the bursting of a huge asset price bubble amid periods of monetary tightening.

By contrast, the UK seems to be heading in the other direction today. Despite holding interest rates at 5% in the last Monetary Policy Committee meeting, the Bank of England indicated it’s on a trajectory towards further easing over the coming months.

Governor Andrew Bailey said interest rates are “now gradually on the path down“. Additional rate cuts could spark some much-needed growth for FTSE 100 share prices.

In this context, I can see the logic behind the latest Goldman Sachs FTSE 100 forecast. The bank predicts the index will surge to 8,800 points within 12 months. As I write, the Footsie’s hovering around the 8,233 level.

A FTSE 100 stock to consider

Identifying which shares in the index appear deeply undervalued can be very lucrative over the long run. One candidate to consider buying is pharma giant GSK (LSE:GSK).

The stock’s forward P/E of 8.64 is well below the average for other companies in the industry and the index as a whole.

GSK also stacks up well on other valuation metrics. A price-to-book (P/B) ratio of 4.4 and price-to-sales (P/S) ratio of 1.8 both indicate a potential bargain.

Granted, long-running litigation concerning the firm’s Zantac heartburn medication continues to cloud the growth outlook. Disappointing sales for the company’s shingles and respiratory syncytial virus (RSV) vaccines are also a cause for concern.

But, I’m pleased to see other areas of the business, including cancer, HIV, and other speciality medicines, are growing fast. The group’s overall revenue performance exceeded expectations in Q2 and FY24 guidance has been upgraded.

Charlie Carman has positions in Goldman Sachs Group and GSK. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »